ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, a gene therapy product candidate to treat patients with recurrent glioblastoma. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has collaboration agreements with Precigen, Inc., MD Anderson Cancer Center, the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ZIOP
Previous Symbol
CUSIP98973P10
Phone617-259-1970
Debt
Debt-to-Equity RatioN/A
Current Ratio5.69
Quick Ratio5.69
Price-To-Earnings
Trailing P/E Ratio-4.32
Forward P/E Ratio-4.58
P/E GrowthN/A
Sales & Book Value
Annual Sales$6.39 million
Price / Sales51.03
Cash FlowN/A
Price / CashN/A
Book Value($0.68) per share
Price / Book-3.37
Profitability
EPS (Most Recent Fiscal Year)($0.53)
Net Income$-54,320,000.00
Net Margins-1,212.13%
Return on EquityN/A
Return on Assets-61.17%
Miscellaneous
Employees46
Outstanding Shares142,380,000
Market Cap$316.08 million
OptionableOptionable
ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions
What is ZIOPHARM Oncology's stock symbol?
ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."
How were ZIOPHARM Oncology's earnings last quarter?
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) issued its earnings results on Wednesday, August, 8th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12). View ZIOPHARM Oncology's Earnings History.
When is ZIOPHARM Oncology's next earnings date?
What price target have analysts set for ZIOP?
3 brokerages have issued 1-year price objectives for ZIOPHARM Oncology's stock. Their forecasts range from $5.50 to $5.50. On average, they expect ZIOPHARM Oncology's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 140.2% from the stock's current price. View Analyst Price Targets for ZIOPHARM Oncology.
What is the consensus analysts' recommendation for ZIOPHARM Oncology?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ZIOPHARM Oncology.
What are Wall Street analysts saying about ZIOPHARM Oncology stock?
Here are some recent quotes from research analysts about ZIOPHARM Oncology stock:
- 1. According to Zacks Investment Research, "ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. " (5/16/2018)
- 2. HC Wainwright analysts commented, "We note that the biopsy analysis from the tumors of patients with rGBM, presented at SNO 2017, showed that Ad-RTS-hIL-12 plus veledimex monotherapy led to upregulation of PD-1 and PD-L1 receptors, suggesting a potential synergy between IL-12 and anti-PD-1 agents. Together with the shift to combinations, management also intends to expand the Ad-RTS-hIL-12 program beyond recurrent glioblastoma (rGBM) to include additional oncologic indications, such as breast cancer and melanoma. We note that the company plans to present an update of the biopsy analysis from the patients with rGBM and advanced breast cancer treated with Ad- RTS-hIL-12 plus veledimex at ASCO on June 4, 2018." (5/14/2018)
Are investors shorting ZIOPHARM Oncology?
ZIOPHARM Oncology saw a increase in short interest in the month of September. As of September 28th, there was short interest totalling 37,823,954 shares, an increase of 0.9% from the September 14th total of 37,502,198 shares. Based on an average daily volume of 1,241,751 shares, the days-to-cover ratio is currently 30.5 days. Approximately 29.1% of the company's stock are short sold. View ZIOPHARM Oncology's Current Options Chain.
Who are some of ZIOPHARM Oncology's key competitors?
Some companies that are related to ZIOPHARM Oncology include Insmed (INSM), Esperion Therapeutics (ESPR), Vanda Pharmaceuticals (VNDA), Arrowhead Pharmaceuticals (ARWR), ImmunoGen (IMGN), Kiniksa Pharmaceuticals (KNSA), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Uniqure (QURE), CannTrust (CNTTF), Zai Lab (ZLAB), Rhythm Pharmaceuticals (RYTM), Lexicon Pharmaceuticals (LXRX), Revance Therapeutics (RVNC) and Akorn (AKRX).
Who are ZIOPHARM Oncology's key executives?
ZIOPHARM Oncology's management team includes the folowing people:
- Dr. Laurence James Neil Cooper, CEO & Director (Age 53)
- Mr. Kevin G. Lafond, Sr. VP of Fin., Chief Accounting Officer & Treasurer (Age 62)
- Dr. David M. Mauney M.D., Exec. VP, Chief Bus. Officer & Interim COO (Age 49)
- Dr. Francois Lebel, Chief Medical Officer and Exec. VP of R&D (Age 66)
- Ms. Lynn M. Ferrucci PHR, Sr. VP of HR, Facilities, IT & Admin.
Who are ZIOPHARM Oncology's major shareholders?
ZIOPHARM Oncology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include First Hawaiian Bank (0.07%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney and Laurence James Neil Cooper. View Institutional Ownership Trends for ZIOPHARM Oncology.
Which major investors are buying ZIOPHARM Oncology stock?
ZIOP stock was bought by a variety of institutional investors in the last quarter, including First Hawaiian Bank. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include David M Md Mauney and Laurence James Neil Cooper. View Insider Buying and Selling for ZIOPHARM Oncology.
How do I buy shares of ZIOPHARM Oncology?
Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ZIOPHARM Oncology's stock price today?
One share of ZIOP stock can currently be purchased for approximately $2.29.
How big of a company is ZIOPHARM Oncology?
ZIOPHARM Oncology has a market capitalization of $316.08 million and generates $6.39 million in revenue each year. The biotechnology company earns $-54,320,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. ZIOPHARM Oncology employs 46 workers across the globe.
What is ZIOPHARM Oncology's official website?
How can I contact ZIOPHARM Oncology?
ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34 NAVY YARD PLAZA, BOSTON MA, 02129. The biotechnology company can be reached via phone at 617-259-1970 or via email at [email protected]
MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe ZIOP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZIOP will underperform the S&P 500 over the long term. You may vote once every thirty days.
